Branded NHS medicine payment rules from July 2026

From 1 July 2026, the rules on what some pharmaceutical companies pay back on branded medicines supplied to the NHS are changing again. The new regulations update the statutory scheme, which is one of the tools the Department of Health and Social Care uses across the UK to keep branded medicine costs within planned limits. (gov.uk) If you are wondering whether this means your prescription will suddenly cost more at the pharmacy, the short answer is no. This law is aimed at manufacturers and suppliers, not patients standing at the counter. That matters, because the legal wording is dense enough to make a funding rule sound like a bedside change. (gov.uk)

The formal name is the Branded Health Service Medicines (Costs) (Amendment) Regulations 2026. In plain English, they amend the 2018 regulations that tell certain companies how much of their eligible branded NHS sales income must be paid back to the Secretary of State. In the legal text this is described by reference to net sales income, but you can read that as the money counted from covered sales to the health service. (gov.uk) A statutory instrument is a way ministers can change detailed rules without passing a brand-new Act each time. That can be practical, but it also means important spending rules often arrive in language ordinary readers would never choose for themselves. (legislation.gov.uk)

The headline change is the rate. The Department of Health and Social Care says the statutory scheme headline payment percentage for newer medicines will be 16.5% for 2026 and after. Because the amendment does not take effect until 1 July 2026, companies that have already been paying the higher 24.3% rate in the first half of 2026 will instead pay 8.7% from 1 July to 31 December 2026. (gov.uk) **What this means:** ministers are not simply giving firms a discount halfway through the year. They are adjusting the second-half rate to reflect the fact that those companies were charged more heavily in the first half, so the full-year position lines up with the new target. (gov.uk)

That lower 8.7% figure can look odd on its own, so it helps to read it beside the number it replaces. The legislation note says 8.7% applies instead of the 16.5% rate that would otherwise have kicked in from the payment table, precisely because some firms already paid 24.3% between January and June 2026. Think of it less as a sudden policy turn and more as a mid-year correction. (gov.uk) The regulations also update the payment table for 2026 and later periods. The legal note refers to “newer presentation” payment percentages, which is a technical category inside the scheme rather than a phrase most readers will ever meet outside legislation. (gov.uk)

To see why the Government is doing this at all, you need one bit of background. Branded medicine costs are controlled through two schemes: a voluntary deal known as VPAG and a statutory scheme for companies outside that deal. Government policy has been to keep them broadly commercially equivalent, meaning not identical but close enough that one scheme does not drift too far away from the other. (gov.uk) According to DHSC’s consultation response published on 10 June 2026, newer-medicines sales data for late 2025 showed slower growth than expected. The department said that reduced the payment required in 2026 and meant the old 24.3% statutory rate was no longer in step with the voluntary scheme, whose 2026 headline rate was 14.5%. (gov.uk)

For the NHS, this is about public money and predictability. The department says both schemes are meant to limit growth in the cost of branded health service medicines while still keeping important medicines available on reasonable terms. Put simply, ministers are trying to protect the health budget without walking away from access to treatment. (gov.uk) For drug companies, though, these percentages are not minor detail. They shape revenue expectations, arguments about the UK market, and complaints about whether Britain is becoming too expensive or too uncertain a place to launch medicines. In the consultation, most respondents disagreed with the proposed 16.5% rate, and many industry voices said the wider system still asks too much of them. (gov.uk)

There is a democratic lesson here as well. Rules that affect NHS funding can move through secondary legislation with very little plain-English explanation attached, even when the sums and stakes are serious. An impact assessment has been published alongside the consultation response, but most people will never read it unless someone translates the process first. (gov.uk) So the shortest useful version is this: from 1 July 2026, the Government is resetting the branded medicines payment rate for the statutory scheme, bringing the headline rate for newer medicines to 16.5%, and giving firms that already paid 24.3% in the first half of the year a reduced 8.7% rate for the second half. It is technical, but the basic idea is simple: how much money drug companies return to the state helps shape how much room the NHS has to spend elsewhere. (gov.uk)